Express Healthcare
Home  »  News  »  Meddo acquires Doxper in cash and stock deal

Meddo acquires Doxper in cash and stock deal

0 145
Read Article

With this acquisition, Meddo is cementing its place as one of the largest health-tech players in the country in the outpatient care space

Meddo has acquired Doxper today in a cash and stock deal. With this acquisition, Meddo is cementing its place as one of the largest health-tech players in the country in the outpatient care space, a statement from Meddo said.

Talking about the rationale behind the acquisition, Saurabh Kochhar, founder and CEO, Meddo, said, “Outpatient care in India today is worse off than where it was a few decades ago – with both trust and transparency in the system flailing. The healthcare journey starts in the clinics for most of us and it should end there for 98 per cent of patients. To enable that, we need tailor-made solutions for India, which would inadvertently rely on network and tech to be able to make a tangible difference at scale. This acquisition is just the leap needed in this very direction. Enabling Meddo’s one-stop care for millions of patients across the Doxper network, in addition to their prescription technology, creates the right ecosystem to fundamentally transform outpatient care, which has been our goal from the get-go.”

Adding to this, Shailesh Prithani, co-founder and CEO, Doxper, said, “In the currently cluttered health-tech space, Meddo stands out with its clear and razor-sharp vision to streamline the unorganised and fragmented outpatient space in the country. The fruition of this goal will mean a significant reduction in hospitalisation and associated cost burden. We believe in Meddo’s omni-channel fulfilment-led approach, and are excited to join this journey. We are confident that our integration will enhance and improve clinical outcomes for clinicians and patients.”

With Doxper in its fold, Meddo plans to scale up its branded full suite clinics to over 1,000 within the next 12-15 months across the 10 top-tier markets within the country, added the statement.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image